9/26) in 1998 approved Herceptin for treatment of advanced HER2-positivecancer that has move beyond the breast. The aggressive create of thedisease is found in about 25% to 30% of breast cancer patients andinvolves extra copies of the HER2 protein the
9/27). Forthe study the women were assigned to one of two groups depending onHER2 status. All patients received chemotherapy before surgery. Patients with HER2-positive disease either received Herceptin withchemotherapy for one year or chemotherapy alone. Thirty-one patientswith HER2-positive inflammatory breast cancer received Herceptin andchemotherapy. According to the results. 55% of patients withinflammatory breast cancer who received a Herceptin-chemotherapycombination had a complete disappearance of the tumors from the breast,compared with 19% of those who received chemotherapy alone. The treatment was "well tolerated with acceptable cardiac safety," Roche said in a statement (Roche release,9/26). Wolfgang Eiermann medical director of the Red Cross Women'sHospital in Munich. Germany said. "Herceptin has been proven to extendlives across the spectrum of HER2-positive disease so these latestfindings ordain be welcome news for the unfortunate few with inflammatorybreast cancer which is an especially devastating create of the disease" (
Forex Groups - Tips on Trading
Related article:
http://www.emaxhealth.com/98/16525.html
comments | Add comment | Report as Spam
|